With the acquisition, responsibility for the site transfers to a young privately owned company. AveThera plans to strategically expand the existing expertise and infrastructure to advance innovative biopharmaceutical solutions. The new owner brings additional perspectives and resources that will enable optimal use of the existing technologies and specialized know-how.
“It is a strong signal that the production capacities and the highly qualified employees at the Braunschweig site will be retained,” says Christian Scherf, Administrative Director of the Helmholtz Centre for Infection Research. “The continuation of operations by AveThera strengthens the innovation campus and opens up new opportunities for collaboration between research and industrial development, as well as for the transfer of technology from research into application.”
Starting March 16, 2026, AveThera will continue production operations in the HZI facilities. Manufacturing will take place under GMP (“Good Manufacturing Practice”) conditions—international quality standards that ensure pharmaceuticals and medical products are produced reliably and safely. Existing capacities will be fully maintained, ensuring that specialized infrastructure, the expertise of experienced professionals, and industrial manufacturing capabilities will remain available at the site in the future.
Statement from AveThera
“The site at Science Campus Braunschweig-Süd offers excellent conditions for further developing modern biopharmaceutical manufacturing processes. We look forward to using the existing infrastructure, expanding our production capacities, and realizing new collaborative and innovation projects together with partners on the Science Campus,” explains AveThera GmbH.
AveThera intends to use the majority of its production capacity for its own product development while also making capacity available for external contract projects. This will create additional opportunities for collaboration with research institutions, spin-offs, and industry partners in the region.
